Short-Term Risk of Bleeding and Stroke Events in Atrial Fibrillation Patients

Study Questions:

What are the safety and effectiveness data for direct oral anticoagulants (DOACs), dabigatran and rivaroxaban, as compared to vitamin K antagonists (VKAs) in anticoagulant-naïve nonvalvular atrial fibrillation (AF) patients during the early phase of anticoagulant therapy?